The Original. Peptides

Analytical Research Compounds

Advance Your
Chemical Exploration.

High-purity analytical compounds engineered for precise in-vitro laboratory research. Independently verified by HPLC for maximum integrity.

≥99% Purity HPLC Verified UK Origin COA Ready Lyophilised
≥99% HPLC Purity
Analytical Grade
United Kingdom Sourcing
The Original. Peptides — Research Vial
Compound Data Vault

Analytical Compound Library

Technical profiles and peer-reviewed research summaries for in-vitro reference. All metrics verified via independent third-party HPLC analysis.

Retatrutide

Triple Receptor Agonist
RETA 40 mg
Formula C224H377N65O66S
Weight 4971.4 g/mol
Purity ≥99% HPLC
Clinical Observations

  • Mean body weight reduction of up to 24.2% observed in clinical models.

    NEJM 2023

  • Significant modulation and reduction of intrahepatic lipid content.

    Nature Med 2024
Target Mechanism GLP-1 / GIP / Glucagon
HPLC Verified

MOTS-c

Mitochondria-derived Peptide
MOT-C 10 mg
Formula C101H152N28O22S2
Weight 2174.6 g/mol
Purity ≥99% HPLC
Clinical Observations

  • Exercise-mimetic effects on systemic metabolic signaling pathways.

    Cell 2015

  • Activation of cellular AMPK and improvement in glucose uptake.

    Nat Comm 2021
Target Mechanism MT-RNR1 · AMPK Pathway
HPLC Verified

GLOW

Multi-component Matrix
GLOW 70 mg
GHK-Cu C14H23CuN6O4 50mg
BPC-157 C62H98N16O22 10mg
TB-500 C212H350N56O78S 10mg
Component Highlights

  • GHK-Cu: Documented stimulation of collagen and elastin synthesis.

    Pickart

  • BPC-157: Observed potentiation of systemic tissue repair models.

    Sikiric
Structure Profile Cu-Complex + Pentadecapeptide
HPLC Verified
Research Visualisation

Clinical Data Highlights

High-fidelity technical infographics derived from published clinical literature and trial results.

Retatrutide (LY3437943)

Phase 2 Trial
Observations.

-86% Mean Reduction in Intrahepatic Lipid Content
-24.2% Mean Body Weight Reduction at 48 Weeks
-14.2 Mean Decrease in Systolic Blood Pressure (mmHg)
72% Participants Reaching Normal Glycemic Status
Reference Data: NEJM 2023 · Nature Medicine 2024
Triple Agonist Profile

Multi-Pathway
Synergy.

GLP-1 Appetite Suppression & Gastric Emptying Modulation
GIP Enhanced Insulin Secretion & Adipose Sensitivity
GCG Glucagon Receptor: Increased Energy Expenditure
Engineered Molecular Integrity
In-Vitro Reference

Research
Integrity.

HPLC Purity Verification Exceeding 99.0% Standards
LYO Vacuum-Sealed Lyophilisation for Stability
UK Direct Laboratory Sourcing & Compliance
Handled Under Professional Supervision Only
Quality Control

The Verification Path

Our commitment to analytical integrity is maintained through a rigorous three-stage verification process for every batch.

01

Molecular Synthesis

Advanced solid-phase peptide synthesis (SPPS) ensures precise amino acid sequencing and structural fidelity from the initial build.

02

HPLC Verification

Independent third-party High-Performance Liquid Chromatography (HPLC) confirms purity levels exceed 99% for all research compounds.

03

Lyophilisation

Freeze-drying in a vacuum environment preserves molecular stability and extends shelf-life for reliable in-vitro laboratory analysis.

Specification Index

Comparative Molecular Data

Technical reference for laboratory characterisation based on validated chemical standards.

Compound Code Molecular Formula MW (g/mol) Receptor / Mechanism Purity Qty Status
Retatrutide RETA C224H377N65O66S 4971.4 GLP-1 / GIP / Glucagon ≥99% 40 mg In Stock
MOTS-c MOT-C C101H152N28O22S2 2174.6 MDP · AMPK Pathway ≥99% 10 mg In Stock
GLOW Blend GLOW Multi-peptide Matrix — Tri-component Stack ≥99% 70 mg In Stock
Support & Procurement

Direct Professional
Support Access.

Speak directly with our team for technical assistance, stock inquiries, or to arrange compound procurement.

Available for technical questions and ordering support.